Objective -To estimate the reduction in the number of children infected with HIV that might be achieved by extending the provision of voluntary antenatal HIV testing. This effect would be mediated by increased numbers of women infected with HIV who receive an intervention to reduce the risk of vertical transmission (for example, zidovudine or caesarean section delivery), who use an alternative to breast feeding, or whose pregnancy is terminated. Setting -London, United Kingdom. Methods -Relevant data were derived from neonatal seroprevalence studies, obstetric and paediatric reporting schemes, and review ofexternal information. Sensitivity analyses were performed for certain parameters.
Abstract
Objective -To estimate the reduction in the number of children infected with HIV that might be achieved by extending the provision of voluntary antenatal HIV testing. This effect would be mediated by increased numbers of women infected with HIV who receive an intervention to reduce the risk of vertical transmission (for example, zidovudine or caesarean section delivery), who use an alternative to breast feeding, or whose pregnancy is terminated. Setting -London, United Kingdom. Methods -Relevant data were derived from neonatal seroprevalence studies, obstetric and paediatric reporting schemes, and review ofexternal information. Sensitivity analyses were performed for certain parameters. Results -Of 106 000 births annually in London, an estimated 169 are to women infected with HIV whose infection is not currently recognised before pregnancy. An estimated 28-33 children born to these women will be infected. Precise prediction ofthe number ofpaediatric HIV infections that could be prevented is difficult because of uncertainty in certain factors, particularly the uptake of antenatal testing and the efficacy and acceptability of interventions to reduce prenatal or perinatal transmission. H a testing programme detected 70% of infected women, none of whom opted for a termination but all of whom exclusively bottle fed and received an intervention which halved the risk of transmission, about 12-16 (42-46%) paediatric HIV infections would be prevented annually.
Conclusions -The estimated cost of preventing each paediatric infection is high, but this should be seen in the context of the lifetime health and social care costs for a child infected with HIV. The feasibility of selective testing should be considered when formulating policies on antenatal HIV testing. Programmes that are introduced should be audited to obtain better estimates of costs and benefits. The issue of antenatal HIV testing has provoked much discussion both within the United Kingdom and elsewhere.r" Since December 1992 the Department of Health, London, has recommended that an HIV test be offered to all women attending for antenatal care in areas of "higher" prevalence, provided that testing is voluntary and confidential." Despite this recommendation, however, routine clinical practice has changed little, and most obstetric units still offer testing on an ad hoc basis." In three of the Thames regions in 1993 an estimated 4% of previously undiagnosed pregnant women had their HIV infection first diagnosed in the antenatal period." Recent results suggesting that administration ofzidovudine to the mother and neonate reduces the risk of vertical transmission of HWS is likely to provide an impetus for an expansion of antenatal testing, particularly in areas with increasing levels of maternal infection." It is clearly important to evaluate quantitatively the potential benefits and costs of such a development.
Two of the advantages of HIV testing are that infected individuals can receive appropriate clinical management and can take precautions to avoid infecting their sexual or drug sharing partners. 15 Those found not to be infected with the virus can receive counselling to reduce risk of acquisition of HIV and other sexually transmitted diseases. Although these considerations are relevant to antenatal testing, the principal rationale for testing in this context should relate directly to the pregnancy.? One advantage is that children born to infected mothers can be closely monitored by paediatricians, allowing for timely prophylactic and therapeutic intervention.I This is arguably less important, however, than the opportunity to avoid or reduce the chance ofhaving an infected child. If the diagnosis is made early in pregnancy an infected woman can make an informed decision as to whether to have the pregnancy terminated. I She can discuss with her obstetrician the options for reducing perinatal transmission, which currently are zidovudine and, possibly, caesarean section delivery." Finally, she can be counselled about the risk of infecting her child through breast feeding. 11 Increasing the uptake of antenatal testing should result, therefore, in a reduction in the number of children infected with HIV. Although highly desirable in human terms, this effect would also have important economic benefits in view of the high health and social care costs for a child infected with HIV. 12 This paper describes a method for estimating the number of paediatric infections that could be prevented through antenatal testing, if various assumptions are made. The method was applied to London, United Kingdom, where antenatal testing programmes are being set up, giving results of direct interest to public health planners. Relevant data were derived from neonatal seroprevalence studies," 14 obstetric and paediatric reporting schemes," and review of external information.
Methods
To estimate the potential reduction in the number of children infected with HIV achieved through antenatal testing a simplified model was developed, which represents the possible paths followed by a pregnant woman infected with HIV, and the risk of transmitting the infection to her child (figure). Table 1 describes the probabilities associated with each path, which constitutes the information required to estimate the reduction.
A proportion P of expectant mothers are infected with HIV. In a proportion R of these women the infection was diagnosed before pregnancy, and antenatal testing has no benefit. The parameter D represents the detection rate of an antenatal testing programme among women infected with HIV not previously aware of their infection. Setting D to zero reflects a scenario where there is no antenatal testing. After a positive antenatal HIV test a proportion A of infected women, who would otherwise have delivered, decide to have the pregnancy terminated. The underlying rate of vertical transmission among children who are not breast fed is TV' Among women whose infection is not recognised, a proportion B breast feed, and their children experience an additional transmission risk, T B' It is assumed that all Additional risk of vertical transmission Review paper 0·07,0'14 through breast feeding recognised infected women comply with the advice not to breast feed and receive an intervention (or combination of interventions) that reduces the risk of transmission to T 1 «Tv).
The overall probability that a child is infected is obtained by summing the probabilities specific to each path (figure):
Setting D equal to zero (no antenatal testing) and subtracting from equation (1) yields the expected number of paediatric infections prevented for each live birth:
A number of the parameters in equation (2) were estimated by using three data sources: reporting schemes for pregnant women infected with HIV and children positive for antibody to HIV,15 and programmes of unlinked, anonymous testing of neonatal dried blood spotS. 13 14 For other parameters external data were reviewed, and ranges of values were examined when precise single estimates were not available.
The proportion of neonatal dried blood spots positive for antibody to HIV provides an estimate of the prevalence of infection in women going to term. This should correspond closely to the proportion of expectant mothers who are infected with HIV (P), though may be a slight underestimate because of women who have their pregnancy terminated after a positive HIV antenatal test. In 1993, of the 103 154 dried blood spots tested in the metropolitan districts of the Thames health regions, 182 were HIV antibody positive, a prevalence of 1·76 per 1000.
The proportion of infected pregnant women whose infection was diagnosed before pregnancy (R) was estimated by combined analysis of data from neonatal serosurveys and reports from obstetricians of live births to infected women. While there were 182 positive neonatal samples in 1993, only 17 births (9%) were reported from women whose HIV infections were diagnosed before pregnancy, giving R = 0·093.
As feeding practices depend on maternal demographic and behavioural characteristics it would be inappropriate to use nationally representative data" to estimate the proportion of infected women, whose infection is not recognised, who breast feed (B). Data on the mode of feeding are collected in the paediatric reporting scheme, and by linkage with the obstetric scheme it is possible to identify mothers whose infection was first recognised after delivery. Since the inception of the schemes, 68 such women have been identified, of whom 43 (63%) breast fed. As almost all these mothers were identified through symptomatic infection in their children, and as breast feeding is a risk factor for transmission, this is an overestimate of B. It is possible to apply an adjustment (Appendix), however, which gives an estimate of 0'462.
There is little information on whether knowledge of HIV infection status acquired through antenatal testing affects the decision to terminate the pregnancy. Two controlled studies of intravenous drug users reported marginally higher termination rates among women who tested antibody positive early enough in pregnancy to have the option of a termination. 17l 8 There is evidence that many, if not most, infected pregnant women in London are African. 14 19 Because termination is unacceptable to many African women on moral and religious grounds" the overall termination rate is unlikely to be high. We examined values between 0% and 40% for the proportion of women opting for a termination as a direct consequence of a positive HIV antenatal test (A), though the lower values in this range are more plausible.
The risk of vertical transmission T v to a child who is not breast fed has been estimated as 0'14. 15 This figure is based on follow up data gathered in the paediatric reporting scheme, the analysis being restricted to mothers who were known, through the obstetric scheme, to be infected before delivery.
While it is widely accepted that breast feeding 0  7  3·8  8·0  12·2  16·3  14  7·7  11·8  16·0  20·2  10  7  5·5  9·2  13·0  16·7  14  9·3  13·1  16·8  20·6  20  7  7·2  10·5  13·8  17·1  14  11·0  14·3  17·7  21·0  30  7  8·8  11·7  14·7  17·6  14  12·7  15·6  18·5  21·4  40  7  10·5  13·0  15·5  18·0  14  14·3  16·8  19·3  21·8 • Assuming 106 000 live births and a 70% detection rate of previously unrecognised maternal infections. The total number of infected children born to women who are not diagnosed before pregnancy is estimated to lie between 29·2 and 34·7.
carries an additional risk of HN transmission, the precise level of risk (TB) has not been determined. An estimate of 0'14 was obtained from a review of prospective studies, but this analysis was unable to assess whether breast fed and bottle fed children were comparable with respect to other risk factors for transmission." Because of evidence that vertical transmission rates in breast fed and bottle fed groups are less divergent than previously thought" we used the lower confidence limit (0'07) and central estimate (0-14) from the review paper. II Ofinterventions to reduce the risk ofprenatal or perinatal transmission, only zidovudine is of proved benefit. A trial, in which zidovudine was given during pregnancy, labour, and to the neonate, was terminated early when a threefold reduction in risk was observed." The trial was conducted in a group with a high underlying rate of transmission, however, and zidovudine may not be as effective in groups with lower rates. There is growing evidence for a protective role of caesarean section delivery, though it has not been evaluated in a randomised controlled trial. The most reliable estimate of its effect is a halving in the odds of transmission. 10 A number of other interventions which might reduce the risk of vertical transmission are under consideration." We consider single or combined interventions that produce proportionate reductions in transmission risk (Tv to T J of 0%, 25%, 50%, and 75%. A 0% reduction is unrealistic in terms of efficacy but shows the effect of an antenatal testing programme if interventions in pregnancy were not used.
A required parameter is the detection rate of previously unrecognised infected pregnancies (D) . In most programmes, however, the only available information is the proportion of all pregnant women who receive a test, often referred to as the uptake rate. This equals the detection rate only if infected and uninfected women are equally likely to be tested. Well organised non-selective testing programmes have typically reported uptake rates of around 70%,23--25 the figure assumed in this analysis for the detection rate. As the number of paediatric infections prevented is directly proportional to the detection rate (equation 2) it is straightforward to examine the impact of a programme that is less or more effective in identifying infected women. Dunn, Nicoll, Holland, Davison Results There are about 106 000 live births annually in London." Based on the seroprevalence from neonatal surveys, there were an estimated 186·6 births to women infected with HIV in 1993.
In an estimated 9'3% of these deliveries (17'4) the mother was diagnosed before pregnancy, leaving 169·2 mothers who could potentially benefit from antenatal testing. If the effect of current testing programmes is ignored, the number of infected children born to these women is estimated to range between 29·2 (7% additional risk through breast feeding) and 34·7 (14% additional risk). This represents the maximum impact that a testing programme could have on reducing the number of children infected with HIV, and percentage reductions are based on these values.
Equation (2) can be used to derive the number of these paediatric infections that could be prevented by antenatal testing (table 2) . These figures are based on a hypothetical testing programme that detects 70% of previously unrecognised maternal infections, with various assumptions about the proportion of women who opt for a termination, the effectiveness of an intervention for reducing vertical transmission, and the additional risk of transmission associated with breast feeding. For example, given a 20% termination rate, a 14% additional risk of transmission through breast feeding, and an intervention (or interventions) that is 25% effective, a predicted 14'3 infections would be prevented.
The table provides an insight into the comparative importance of the different ways by which the number of paediatric infections might be reduced. The proportion of infected women who opt for a termination has a weak effect (within the range examined), particularly when the intervention for reducing perinatal transmission is highly effective. The avoidance of breast feeding would potentially prevent between 3·8 and 7·7 infections. The most important determinant is the acceptability and efficacy of interventions that reduce the risk of prenatal or perinatal transmission. A conservative estimate of the effect of zidovudine is a 50% reduction in transmission risk, and there may be an additional effect of caesarean section delivery. If all women accepted an intervention (or interventions) that was 50% effective then between 12·2 and 16·0 (42-46%) paediatric infections could be prevented annually, even if a positive antenatal test had no bearing on the decision to have the pregnancy terminated. An additional 0'8 infections could be prevented for every 10% increment in the termination rate.
The method is easily modified to examine the effect of a testing programme that achieved a lower overall detection rate, which might arise for example under a policy of selective testing. To estimate the number of paediatric infections that could be prevented by a programme achieving a detection rate of 50%, say, the cells in table 2 are scaled by the factor 50/ 70. Currently, infection is diagnosed before pregnancy in 9% of infected pregnant women; among the remaining 91 % who are un-diagnosed, antenatal testing detects an approximate additional 4% ofwomen.' Antenatal testing is therefore preventing, under the most favourable assumptions, an estimated 1·2 (21'8 x 4/70) paediatric infections annually.
Discussion
It is important to emphasise that these results are reliable only in the short term. For example, if maternal positivity for antibody to HIV continues to rise" antenatal testing should help prevent a larger number of paediatric HIV infections. Other parameters might also change over time, including the proportion ofpregnant women infected with HIV whose infection is recognised before pregnancy and, because it is related to the duration of infection of an individual woman," the underlying risk of vertical transmission.
We made the simplifying assumptions that all women who are aware that they are infected with HIV refrain from breast feeding and receive an intervention that reduces the risk of transmitting the virus to their fetus. Experience indicates that about 5% of mothers with a recognised infection do breast feed," but this does not materially alter the findings, The obstetric management of infected women has, to date, generally been no different from that of uninfected women." However, administration ofzidovudine (where it is affordable) may soon become standard prevention strategy," as might caesarean section delivery in the longer term. The extent to which infected women, especially those from ethnic minority groups and those becoming aware of their infection during pregnancy, will accept interventions is unknown. The method has also not taken into account any effect that knowledge ofHIV status might have on future reproductive behaviour. If fertility is reduced the impact of antenatal testing on the number of paediatric infections will be stronger than these results suggest.
The focus of this paper is the effect of antenatal testing upon the number of paediatric HIV infections. A comprehensive evaluation would need to consider other consequences of testing, both advantageous 1 and detrimental.i? None the less, it is instructive to estimate the monetary cost of screening for each paediatric infection that is prevented. The costs of counselling and performing an HIV antibody test have been estimated, excluding capital costs and the provision of treatment for infected women and children, at £2.33 and £7.21 respectively.? If these estimates are accurate" a programme covering London with a 70% uptake of testing would cost £780000 annually. If infected and uninfected women are equally likely to accept testing then the extreme estimates in table 2 suggest a figure between £36 000 and £205 000 for each paediatric infection prevented. Although this cost appears prohibitively high, it needs to be set against the considerable health and social care costs for a child infected with HIV. 12 Given the wide variation in levels ofmaternal HIV infection by area of residence, centre attended for obstetric care, and between women 39 from different behavioural and demographic groups," consideration should be given to alternatives to universal testing. 1 For example, testing might be focused in obstetric centres with comparatively high prevalence of maternal infection or selectively offered to women with an identifiable risk factor, such as intravenous drug users or migrants from a high prevalence area, such as sub-Saharan Africa. While a selective testing policy would almost certainly result in a lower overall detection rate of infected women than a universal testing pOlicy,3O it might be considerably more cost effective. 1 This analysis has been based on costs and effects of antenatal testing programmes that are largely conjectural. If programmes are introduced it is important that they are thoroughly audited." This should include assessments of monetary costs and public health benefits; of the uptake rate and its determinants; of anxiety caused to uninfected women; and of the consequences of a positive test result, both for obstetric management and in a wider psychological and social context. Such assessments would need to combine quantitative and qualitative research. Finally, it should be recognised that the method we have described might be applied to any setting where the necessary information was available or could be estimated. 
